Matinas

BioNTechs headquarters

Biotech

BioNTech axes oral mRNA project after tech flunks early test

An initial mouse study failed to show preclinical activity—leading BioNTech to join Gilead on the list of companies to dump Matinas in recent months.

Nick Paul Taylor May 11, 2023 7:20am

Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program

Gilead nixes oral COVID-19 antiviral to focus on internal asset

Jan 31, 2023 6:40am